PMPRB has produced its 2018 pipeline report, showing the most exciting medicines due to come to market in the foreseeable future.
Approximately 6,000 medicines in pharmaceutical pipelines were examined, with the report highlighting the Patented Medicine Prices Review Board’s (PMPRB) top 30. These products target an unmet medical need, often for serious conditions, and represent a step-up from the treatments currently available.
The 30 products identified include nine gene therapies, demonstrating the shifting landscape of the current pharmaceutical environment.
“This element of our annual horizon scanning exercise is part of a suite of PMPRB publications that tackle pharmaceutical issues. Together with its companion publication, Meds Entry Watch, it encompasses the continuum of new and emerging medicines in Canada and internationally.”